Compare MRVI & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRVI | LEO |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.8M | 395.5M |
| IPO Year | 2020 | N/A |
| Metric | MRVI | LEO |
|---|---|---|
| Price | $2.86 | $6.09 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.13 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 140.2K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.01% |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $185,743,000.00 | N/A |
| Revenue This Year | $12.44 | N/A |
| Revenue Next Year | $7.90 | N/A |
| P/E Ratio | ★ N/A | $151.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.67 | $5.67 |
| 52 Week High | $4.11 | $6.55 |
| Indicator | MRVI | LEO |
|---|---|---|
| Relative Strength Index (RSI) | 33.93 | 31.21 |
| Support Level | $2.57 | $5.77 |
| Resistance Level | $2.88 | $6.37 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 4.73 | 18.75 |
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products include equity and fixed income mutual funds, retail money market funds, government/treasury money market funds, institutional money market funds, and others. The company and its affiliates, as well as others involved in the management, sales, investment activities, business operations, or distribution of the fund, are engaged in businesses and have interests other than those of managing the fund.